NASDAQ:CALA - Calithera Biosciences Stock Price, Price Target & More

Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."

Calithera Biosciences Inc (NASDAQ:CALA) issued its quarterly earnings results on Thursday, May, 10th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.32) by $0.05. The biotechnology company had revenue of $5.19 million for the quarter, compared to analysts' expectations of $7.28 million. Calithera Biosciences had a negative return on equity of 22.92% and a negative net margin of 131.51%. View Calithera Biosciences' Earnings History.

3 brokers have issued 12 month target prices for Calithera Biosciences' shares. Their forecasts range from $14.00 to $14.00. On average, they anticipate Calithera Biosciences' stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 201.1% from the stock's current price. View Analyst Ratings for Calithera Biosciences.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Calithera Biosciences saw a drop in short interest in the month of June. As of June 29th, there was short interest totalling 1,468,140 shares, a drop of 32.1% from the June 15th total of 2,163,551 shares. Based on an average daily volume of 622,955 shares, the days-to-cover ratio is presently 2.4 days. Currently, 5.1% of the company's stock are short sold. View Calithera Biosciences' Current Options Chain.

Some companies that are related to Calithera Biosciences include Collegium Pharmaceutical (COLL), Arbutus Biopharma (ABUS), Geron (GERN), Aclaris Therapeutics (ACRS), Odonate Therapeutics (ODT), ChemoCentryx (CCXI), Five Prime Therapeutics (FPRX), Theratechnologies (THERF), Progenics Pharmaceuticals (PGNX), TIGENIX/S (TIG), Viking Therapeutics (VKTX), Akebia Therapeutics (AKBA), Prothena (PRTA), Insys Therapeutics (INSY) and Obseva (OBSV).

Headlines about CALA stock have been trending somewhat positive on Thursday, Accern Sentiment reports. The research group ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Calithera Biosciences earned a news impact score of 0.09 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 47.64 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CALA stock can currently be purchased for approximately $4.65.

Calithera Biosciences has a market capitalization of $161.30 million and generates $25.95 million in revenue each year. The biotechnology company earns $-27,820,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Calithera Biosciences employs 73 workers across the globe.

Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-870-1000 or via email at [email protected]